Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$3.30 ▼ -0.09
(-2.80%)
MKT CAP: $406.0M • VOL: 2.72M
52W L $2 52W H $5
CCCC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $35.9M | $35.6M | $20.8M |
| YoY Revenue Growth % | +1.0% | +71.4% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$115.2M | -$119.6M | -$139.0M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$105.0M | -$105.3M | -$132.5M |
| EBITDA (Normalized) | -$114.7M | -$119.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$98.7M | -$65.2M | -$106.8M |
| Capital Expenditures (CapEx) | $607.0K | $180.0K | — |
| Free Cash Flow (FCF) | -$99.3M | -$65.3M | -$106.8M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $74.6M | $55.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $256.6M | $216.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CCCC.